Eli Lilly CEO tells CNBC one-third of new GLP

Billy Odell Tucker-Robinson Founder & Host — Banking With Billy Network • Financial Intelligence • Markets • World News • Independent Analysis
Published: 2026-09-22 • Permanent link

Fueled by Eli Lilly's growing production, a significant portion of new GLP-1 patients are turning to Foundayo. According to CNBC, the drugmaker has seen one-third of its new patients taking the medication, a trend that is expected to continue as the company ramps up production. This development has sparked interest among investors, who are closely watching the company's production levels and patient engagement. Foundayo's success has also led to a surge in shares, with Eli Lilly's stock price rising by over 10% in the past week.

Rising demand for GLP-1 treatments has significant implications for the broader healthcare industry. As the number of patients taking Foundayo increases, Eli Lilly is likely to see a corresponding increase in revenue. This, in turn, could lead to a shift in the balance of power among pharmaceutical companies, with Eli Lilly emerging as a major player in the GLP-1 market. Furthermore, the success of Foundayo could lead to increased investment in research and development, driving innovation in the treatment of type 2 diabetes.

The GLP-1 market has experienced significant growth in recent years, driven by the increasing awareness of the condition and the development of new treatments. Since the launch of the first GLP-1 medication in 2012, the market has grown from a small niche player to a major force in the pharmaceutical industry. Eli Lilly's Foundayo is the latest addition to this market, and its success is likely to be closely watched by analysts and investors. According to a recent report by Deloitte, the GLP-1 market is expected to reach $10 billion by 2025.

As Eli Lilly continues to ramp up production of Foundayo, investors will be watching closely for any updates on the company's production levels and patient engagement. The company has announced plans to increase production by 20% in the coming months, which could lead to a further increase in shares. However, there are also risks associated with the company's growth, including increased competition from other pharmaceutical companies and potential regulatory challenges. With the GLP-1 market expected to continue growing in the coming years, Eli Lilly's success with Foundayo is likely to be a key catalyst for the company's future growth.